Work

Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma

Year: 2023

Type: article

Study design: Clinical Trial

Source: Hematological Oncology

DOI: 10.1002/hon.3227

Authors: Ying Zhang, Hongzhi Geng, Liangyu Zeng, Jiaqi Li, Qin Yang, Sixun Jia, Xiangping Zong, Wenzhi Cai, Shuangzhu Liu, Yutong Lu, Lei Yu, Caixia Li, Depei Wu

Institutions: Soochow University, First Affiliated Hospital of Soochow University, East China Normal University

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Natural Science Foundation of China

Award: G5394299857

OpenAlex ID: W4387216665

FWCI: 1.34

Cites: 42

Cited by: 13

Related to: 10